Drug updated on 12/11/2024
| Dosage Form | Tablet (oral; 20 mg, 40 mg, 100 mg) |
| Drug Class | Kinase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, previously treated with two or more tyrosine kinase inhibitors (TKIs)
- Indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase with the T315I mutation.
Latest News
Summary
- This summary is based on the review of one systematic review/meta-analysis. [1]
- Asciminib demonstrated a Major Molecular Response (MMR) rate of 23.3–25.5% at 6 months, which is higher than bosutinib (13.2%) and omacetaxine (19.2%) but comparable to the lower range of ponatinib (19.0–66.7%).
- In terms of Complete Cytogenetic Response (CCyR), asciminib achieved a rate of 38.7–40.8% at 6 months, exceeding the rates of omacetaxine (16.1%) and bosutinib (18–24.2%), while falling within the range of ponatinib (21.4–64.8%).
- The study focuses on adult patients with Chronic Phase-Chronic Myeloid Leukemia (CP-CML) who had been treated with ≥2 prior Tyrosine Kinase Inhibitors (TKIs), but no subgroup-specific findings or population characteristics were detailed.
- There is no safety information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Scemblix (asciminib) Prescribing Information. | 2024 | Novartis Pharmaceuticals Corporation, East Hanover, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review | 2023 | Therapeutic Advances in Hematology |